We intend to capitalize on our management team’s experience and expertise to identify unique acquisition opportunities in the biopharmaceutical sector, with a focus on disruptive technologies with the potential to transform healthcare and dramatically improve the lives of patients.
We believe our ability to complete our business combination will be enhanced by our sponsor’s affiliation with Rapha Capital Management, LLC (“RCM”) and RNA Advisors, LLC (“RNA”).
RCM is an investment management firm located in Miami, Florida focused on identifying and managing strategic investments in early stage, non-public biotechnology companies, with a strategy of identifying and growing revolutionary and disruptive ideas in medicine, healthcare, and biotechnology before others can see their value. RCM executes its investment strategy by making equity and convertible debt investments in privately held companies that RCM believes have developed a transformative product, technology, or process that will drive long-term value creation for shareholders. RCM’s portfolio companies currently focus on a wide range of targets, including immunotherapies, medical devices, ocular diseases, genome editing, cell and gene therapy and bioprinting.
According to RCM’s Founder and Managing Partner, Kevin Slawin, M.D., successfully identifying future successful biotech investment targets at, or just prior to, the Series A stage requires a wide range of knowledge, experience, and a little bit of luck. He believes there is no “formula” that can be applied by investment “technicians” to reliably identify future successful companies. Dr. Slawin has a unique mix of experience as a robotic oncologic surgeon, academician, basic and clinical researcher, biotech founder and investor, as well as public biotech operator. His expertise is focused in disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. Dr. Slawin is also the founder of Bellicum Pharmaceuticals, Inc., which he successfully took public in an approximately $161 million initial public offering (“IPO”) in December 2014. He also plays a guiding role in several of the investments managed by RCM in certain companies, for instance, serving as a board member at 3DBio Therapeutics, Inc., FIZE Medical, Inc., K-2 Biolabs Acclerator, LLC and Demeetra AgBio, Inc. He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc., engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in 2020. He is the founder and CEO of PONCE Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, reuniting the team that founded Bellicum Pharmaceuticals to focus on the anti-aging space, which he believes will soon rival oncology in both interest and value. He is the founder and managing partner of Miami Medicos, LLC, a growing group of physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami and South Florida.
He is co-Inventor of the FDA-approved “prostate health index (PHI)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published in medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). In addition to his publications, Dr. Slawin has also been listed in America’s Top Doctors for Cancer (Castle Connolly Medical). RCM manages Rapha Capital Investment I through XIII, which are thirteen legacy special purpose investment vehicles (“SPIVs”) that currently manage early-stage biotech investments since it was formed in2017. RCM also manages Rapha Capital BioVentures Fund I, LP (the “RCBV Fund”) that is also solely focused on investment in early-stage life science companies, and that builds on the experience, success and investor base from Rapha Capital I – XIII.
RNA Advisors is a financial, strategic and transaction advisory services firm which focuses almost exclusively on life sciences and healthcare technology. RNA’s team has completed multiple transactions in these sectors by leveraging their industry expertise and capital markets experience to provide acquirers, targets, lenders and investors with compelling, tailored, data driven analyses to support financial, strategic and transactional objectives. RCM, supported by insight and analysis from RNA, will select an optimal investment target for acquisition.
Dr. Slawin, the founder of Rapha Capital Management and the Chief Strategic Officer of ARCK, is focused on identifying and growing revolutionary and disruptive ideas in medicine, healthcare, and biotechnology, before others can see their value. Rapha Capital executes its investment strategy by making equity and convertible debt investments in privately held or public companies that RCM believes have developed a transformative product, technology, or process that will drive long-term value creation for shareholders. Dr. Slawin, along with RNA and the investment team, will extend this strategy to find a merger target that yields outstanding long term value to investors in the ARCK SPAC.
- Experienced Management Team
- Successful Track Record in Early-Stage Biotech Investing
- Unique Partnership with Rapha Capital Management
- RNA Provides Deep Industry Knowledge and Fin Analysis
- Focus on Wide Range of Targets in the Biopharma Sector
- Significant Operational Value-Add Capabilities
While we may pursue an acquisition opportunity in any industry or sector, we intend to capitalize on our management team’s experience and expertise to identify attractive acquisition opportunities in the biopharmaceutical sector, with a focus on disruptive technologies with the potential to transform healthcare and dramatically improve the lives of patients. We anticipate evaluating high quality biopharmaceutical and medical technology companies domiciled in the United States and other developed countries as potential targets.
Experienced Investment Team
Ivan Kaufman serves as our Chief Executive Officer and Chairman of our board of directors.
Mr. Kaufman has extensive experience operating a diverse array of companies
Kevin Slawin, MD
Kevin Slawin serves as our Chief Strategy Officer and is a member of our board of directors. Dr. Kevin Slawin, M.D. is the Founder and Managing Partner at RCM.
Paul Elenio serves as our Chief Financial Officer. Mr. Elenio also currently serves as the Chief
Financial Officer of ART, a position he has held since 2005.
William Connolly serves as our Secretary and Vice President. Mr. Connolly also currently serves as the Executive Vice President & Special Counsel at ART.
John Natalone serves as our treasurer. Since 2008, Mr. Natalone also has served as the Executive Vice President — Treasury and Servicing at ART
Cyrus D. Walker
Mr. Walker currently serves as Chief Executive Officer of The Dibble Group, an insurance brokerage and consulting firm he founded in 2018. From January 2000, he worked in several roles at Nemco Group, LLC
Mr. Modlin is a self-made executive who made his mark on the Manhattan real estate industry by age twenty seven. Mr. Modlin currently serves as the Chief Executive Officer of A.
Mr. Mack currently serves as the Chief Executive Officer and Executive Chairman of Sightly Enterprises, Inc., a marketing and media technology company, focused on digital video advertising and analytics.